Global Beta blockers
Global Beta blockers

Beta blockers Comprehensive Study by Type (Non-selective antagonists, Selective β1-antagonists), Application (Abnormal Heart Rhythms, Hypertension), Generation (1st Generation, 2nd Generation, 3rd Generation) Players and Region - Global Market Outlook to 2027

Beta blockers Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027  

Apr 2022 Edition 220 Pages 161 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Beta blockers Market?

Beta blockers also called beta-adrenergic blocking agents are medications that reduce blood pressure. Also, it helps widen veins and arteries to improve blood flow. Beta-blockers are used to manage cardiac arrhythmias, heart failure, high coronary artery disease risk, diabetes, post-heart attack, angina pectoris because of coronary atherosclerosis, and hypertension.

The market study is being classified by Type (Non-selective antagonists and Selective β1-antagonists), by Application (Abnormal Heart Rhythms and Hypertension) and major geographies with country level break-up.

Laboratoires Pierre Fabre (France), Lupin Limited (India), GlaxoSmithKline (United Kingdom), ANIP Acquisition Company (United States), Mylan (United States), Novartis (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical (Israel), King Pharmaceuticals (United States) and Amneal Pharmaceuticals (United States) are some of the key players profiled in the study.

Global Beta Blockers is a fragmented market due to the presence of various players. The players are focusing on investing more in Launching Products. These will enhance their market presence. The companies are also planning strategic activities like partnerships, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge.

Segment Analysis
Analyst at AMA have segmented the market study of Global Beta blockers market by Type, Application and Region.

On the basis of geography, the market of Beta blockers has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Application of Beta Blockers to treat a wide range of Health Issues like Heart Problems, Anxiety Attacks
  • Rapid Growth of Geriatric Population Worldwide

Market Trend
  • Rising Heart Related Issues
  • Technical Progress in Healthcare Sector

Restraints
  • Concerns Related to the Severe Asthma Attacks

Opportunities
  • Increasing Patients with Hypertension and Heart Diseases, and Lack of Proper Treatment
  • Lack of Physical Exercise Coupled With Poor Diet

Challenges
  • Government Guidelines on the Packaging Labels of Beta Blockers


Market Leaders and some development strategies
On 9th March 2021, ANIP Acquisition Company announced the acquisition of Novitium Pharma. The transaction has been approved by the ANI Board of Directors. The acquisition will strengthen ANIís well-established Generics business with enhanced development capabilities and increased focus on niche opportunities.
On 28th May 2019, Teva Pharmaceutical has launch a generic version of Ranexa (ranolazine), is an extended-release tablet of 500 mg and 1000 mg, in the United States. The tablets are indicated for the treatment of chronic angina. Ranolazine Extended-Release Tablets may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers.


Key Target Audience
Beta Blockers Manufacturers, Beta Blockers Suppliers and Distributors, Regulatory Bodies, Potential Investors, Research and Development Institutes and Others

Frequently Asked Questions (FAQ):

1. Which factors would majorly drive the Beta blockers Market?
"Increasing Application of Beta Blockers to treat a wide range of Health Issues like Heart Problems, Anxiety Attacks " is seen as one of major growth factors of Beta blockers Market in years to come.

2. Can we have customized study for Beta blockers Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. Which region will lead the Global Beta blockers Market?
will lead Beta blockers Market in coming years.
Report Objectives / Segmentation Covered
By Type
  • Non-selective antagonists
  • Selective β1-antagonists
By Application
  • Abnormal Heart Rhythms
  • Hypertension
By Generation
  • 1st Generation
  • 2nd Generation
  • 3rd Generation

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Application of Beta Blockers to treat a wide range of Health Issues like Heart Problems, Anxiety Attacks
      • 3.2.2. Rapid Growth of Geriatric Population Worldwide
    • 3.3. Market Challenges
      • 3.3.1. Government Guidelines on the Packaging Labels of Beta Blockers
    • 3.4. Market Trends
      • 3.4.1. Rising Heart Related Issues
      • 3.4.2. Technical Progress in Healthcare Sector
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Beta blockers, by Type, Application, Generation and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Beta blockers (Value)
      • 5.2.1. Global Beta blockers by: Type (Value)
        • 5.2.1.1. Non-selective antagonists
        • 5.2.1.2. Selective β1-antagonists
      • 5.2.2. Global Beta blockers by: Application (Value)
        • 5.2.2.1. Abnormal Heart Rhythms
        • 5.2.2.2. Hypertension
      • 5.2.3. Global Beta blockers by: Generation (Value)
        • 5.2.3.1. 1st Generation
        • 5.2.3.2. 2nd Generation
        • 5.2.3.3. 3rd Generation
      • 5.2.4. Global Beta blockers Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Australia
          • 5.2.4.2.6. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Beta blockers (Price)
      • 5.3.1. Global Beta blockers by: Type (Price)
  • 6. Beta blockers: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Laboratoires Pierre Fabre (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Lupin Limited (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. ANIP Acquisition Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Mylan (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teva Pharmaceutical (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. King Pharmaceuticals (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Amneal Pharmaceuticals (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Beta blockers Sale, by Type, Application, Generation and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Beta blockers (Value)
      • 7.2.1. Global Beta blockers by: Type (Value)
        • 7.2.1.1. Non-selective antagonists
        • 7.2.1.2. Selective β1-antagonists
      • 7.2.2. Global Beta blockers by: Application (Value)
        • 7.2.2.1. Abnormal Heart Rhythms
        • 7.2.2.2. Hypertension
      • 7.2.3. Global Beta blockers by: Generation (Value)
        • 7.2.3.1. 1st Generation
        • 7.2.3.2. 2nd Generation
        • 7.2.3.3. 3rd Generation
      • 7.2.4. Global Beta blockers Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Australia
          • 7.2.4.2.6. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Beta blockers (Price)
      • 7.3.1. Global Beta blockers by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Beta blockers: by Type(USD Million)
  • Table 2. Beta blockers Non-selective antagonists , by Region USD Million (2016-2021)
  • Table 3. Beta blockers Selective β1-antagonists , by Region USD Million (2016-2021)
  • Table 4. Beta blockers: by Application(USD Million)
  • Table 5. Beta blockers Abnormal Heart Rhythms , by Region USD Million (2016-2021)
  • Table 6. Beta blockers Hypertension , by Region USD Million (2016-2021)
  • Table 7. Beta blockers: by Generation(USD Million)
  • Table 8. Beta blockers 1st Generation , by Region USD Million (2016-2021)
  • Table 9. Beta blockers 2nd Generation , by Region USD Million (2016-2021)
  • Table 10. Beta blockers 3rd Generation , by Region USD Million (2016-2021)
  • Table 11. South America Beta blockers, by Country USD Million (2016-2021)
  • Table 12. South America Beta blockers, by Type USD Million (2016-2021)
  • Table 13. South America Beta blockers, by Application USD Million (2016-2021)
  • Table 14. South America Beta blockers, by Generation USD Million (2016-2021)
  • Table 15. Brazil Beta blockers, by Type USD Million (2016-2021)
  • Table 16. Brazil Beta blockers, by Application USD Million (2016-2021)
  • Table 17. Brazil Beta blockers, by Generation USD Million (2016-2021)
  • Table 18. Argentina Beta blockers, by Type USD Million (2016-2021)
  • Table 19. Argentina Beta blockers, by Application USD Million (2016-2021)
  • Table 20. Argentina Beta blockers, by Generation USD Million (2016-2021)
  • Table 21. Rest of South America Beta blockers, by Type USD Million (2016-2021)
  • Table 22. Rest of South America Beta blockers, by Application USD Million (2016-2021)
  • Table 23. Rest of South America Beta blockers, by Generation USD Million (2016-2021)
  • Table 24. Asia Pacific Beta blockers, by Country USD Million (2016-2021)
  • Table 25. Asia Pacific Beta blockers, by Type USD Million (2016-2021)
  • Table 26. Asia Pacific Beta blockers, by Application USD Million (2016-2021)
  • Table 27. Asia Pacific Beta blockers, by Generation USD Million (2016-2021)
  • Table 28. China Beta blockers, by Type USD Million (2016-2021)
  • Table 29. China Beta blockers, by Application USD Million (2016-2021)
  • Table 30. China Beta blockers, by Generation USD Million (2016-2021)
  • Table 31. Japan Beta blockers, by Type USD Million (2016-2021)
  • Table 32. Japan Beta blockers, by Application USD Million (2016-2021)
  • Table 33. Japan Beta blockers, by Generation USD Million (2016-2021)
  • Table 34. India Beta blockers, by Type USD Million (2016-2021)
  • Table 35. India Beta blockers, by Application USD Million (2016-2021)
  • Table 36. India Beta blockers, by Generation USD Million (2016-2021)
  • Table 37. South Korea Beta blockers, by Type USD Million (2016-2021)
  • Table 38. South Korea Beta blockers, by Application USD Million (2016-2021)
  • Table 39. South Korea Beta blockers, by Generation USD Million (2016-2021)
  • Table 40. Australia Beta blockers, by Type USD Million (2016-2021)
  • Table 41. Australia Beta blockers, by Application USD Million (2016-2021)
  • Table 42. Australia Beta blockers, by Generation USD Million (2016-2021)
  • Table 43. Rest of Asia-Pacific Beta blockers, by Type USD Million (2016-2021)
  • Table 44. Rest of Asia-Pacific Beta blockers, by Application USD Million (2016-2021)
  • Table 45. Rest of Asia-Pacific Beta blockers, by Generation USD Million (2016-2021)
  • Table 46. Europe Beta blockers, by Country USD Million (2016-2021)
  • Table 47. Europe Beta blockers, by Type USD Million (2016-2021)
  • Table 48. Europe Beta blockers, by Application USD Million (2016-2021)
  • Table 49. Europe Beta blockers, by Generation USD Million (2016-2021)
  • Table 50. Germany Beta blockers, by Type USD Million (2016-2021)
  • Table 51. Germany Beta blockers, by Application USD Million (2016-2021)
  • Table 52. Germany Beta blockers, by Generation USD Million (2016-2021)
  • Table 53. France Beta blockers, by Type USD Million (2016-2021)
  • Table 54. France Beta blockers, by Application USD Million (2016-2021)
  • Table 55. France Beta blockers, by Generation USD Million (2016-2021)
  • Table 56. Italy Beta blockers, by Type USD Million (2016-2021)
  • Table 57. Italy Beta blockers, by Application USD Million (2016-2021)
  • Table 58. Italy Beta blockers, by Generation USD Million (2016-2021)
  • Table 59. United Kingdom Beta blockers, by Type USD Million (2016-2021)
  • Table 60. United Kingdom Beta blockers, by Application USD Million (2016-2021)
  • Table 61. United Kingdom Beta blockers, by Generation USD Million (2016-2021)
  • Table 62. Netherlands Beta blockers, by Type USD Million (2016-2021)
  • Table 63. Netherlands Beta blockers, by Application USD Million (2016-2021)
  • Table 64. Netherlands Beta blockers, by Generation USD Million (2016-2021)
  • Table 65. Rest of Europe Beta blockers, by Type USD Million (2016-2021)
  • Table 66. Rest of Europe Beta blockers, by Application USD Million (2016-2021)
  • Table 67. Rest of Europe Beta blockers, by Generation USD Million (2016-2021)
  • Table 68. MEA Beta blockers, by Country USD Million (2016-2021)
  • Table 69. MEA Beta blockers, by Type USD Million (2016-2021)
  • Table 70. MEA Beta blockers, by Application USD Million (2016-2021)
  • Table 71. MEA Beta blockers, by Generation USD Million (2016-2021)
  • Table 72. Middle East Beta blockers, by Type USD Million (2016-2021)
  • Table 73. Middle East Beta blockers, by Application USD Million (2016-2021)
  • Table 74. Middle East Beta blockers, by Generation USD Million (2016-2021)
  • Table 75. Africa Beta blockers, by Type USD Million (2016-2021)
  • Table 76. Africa Beta blockers, by Application USD Million (2016-2021)
  • Table 77. Africa Beta blockers, by Generation USD Million (2016-2021)
  • Table 78. North America Beta blockers, by Country USD Million (2016-2021)
  • Table 79. North America Beta blockers, by Type USD Million (2016-2021)
  • Table 80. North America Beta blockers, by Application USD Million (2016-2021)
  • Table 81. North America Beta blockers, by Generation USD Million (2016-2021)
  • Table 82. United States Beta blockers, by Type USD Million (2016-2021)
  • Table 83. United States Beta blockers, by Application USD Million (2016-2021)
  • Table 84. United States Beta blockers, by Generation USD Million (2016-2021)
  • Table 85. Canada Beta blockers, by Type USD Million (2016-2021)
  • Table 86. Canada Beta blockers, by Application USD Million (2016-2021)
  • Table 87. Canada Beta blockers, by Generation USD Million (2016-2021)
  • Table 88. Mexico Beta blockers, by Type USD Million (2016-2021)
  • Table 89. Mexico Beta blockers, by Application USD Million (2016-2021)
  • Table 90. Mexico Beta blockers, by Generation USD Million (2016-2021)
  • Table 91. Beta blockers: by Type(USD/Units)
  • Table 92. Company Basic Information, Sales Area and Its Competitors
  • Table 93. Company Basic Information, Sales Area and Its Competitors
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Beta blockers: by Type(USD Million)
  • Table 103. Beta blockers Non-selective antagonists , by Region USD Million (2022-2027)
  • Table 104. Beta blockers Selective β1-antagonists , by Region USD Million (2022-2027)
  • Table 105. Beta blockers: by Application(USD Million)
  • Table 106. Beta blockers Abnormal Heart Rhythms , by Region USD Million (2022-2027)
  • Table 107. Beta blockers Hypertension , by Region USD Million (2022-2027)
  • Table 108. Beta blockers: by Generation(USD Million)
  • Table 109. Beta blockers 1st Generation , by Region USD Million (2022-2027)
  • Table 110. Beta blockers 2nd Generation , by Region USD Million (2022-2027)
  • Table 111. Beta blockers 3rd Generation , by Region USD Million (2022-2027)
  • Table 112. South America Beta blockers, by Country USD Million (2022-2027)
  • Table 113. South America Beta blockers, by Type USD Million (2022-2027)
  • Table 114. South America Beta blockers, by Application USD Million (2022-2027)
  • Table 115. South America Beta blockers, by Generation USD Million (2022-2027)
  • Table 116. Brazil Beta blockers, by Type USD Million (2022-2027)
  • Table 117. Brazil Beta blockers, by Application USD Million (2022-2027)
  • Table 118. Brazil Beta blockers, by Generation USD Million (2022-2027)
  • Table 119. Argentina Beta blockers, by Type USD Million (2022-2027)
  • Table 120. Argentina Beta blockers, by Application USD Million (2022-2027)
  • Table 121. Argentina Beta blockers, by Generation USD Million (2022-2027)
  • Table 122. Rest of South America Beta blockers, by Type USD Million (2022-2027)
  • Table 123. Rest of South America Beta blockers, by Application USD Million (2022-2027)
  • Table 124. Rest of South America Beta blockers, by Generation USD Million (2022-2027)
  • Table 125. Asia Pacific Beta blockers, by Country USD Million (2022-2027)
  • Table 126. Asia Pacific Beta blockers, by Type USD Million (2022-2027)
  • Table 127. Asia Pacific Beta blockers, by Application USD Million (2022-2027)
  • Table 128. Asia Pacific Beta blockers, by Generation USD Million (2022-2027)
  • Table 129. China Beta blockers, by Type USD Million (2022-2027)
  • Table 130. China Beta blockers, by Application USD Million (2022-2027)
  • Table 131. China Beta blockers, by Generation USD Million (2022-2027)
  • Table 132. Japan Beta blockers, by Type USD Million (2022-2027)
  • Table 133. Japan Beta blockers, by Application USD Million (2022-2027)
  • Table 134. Japan Beta blockers, by Generation USD Million (2022-2027)
  • Table 135. India Beta blockers, by Type USD Million (2022-2027)
  • Table 136. India Beta blockers, by Application USD Million (2022-2027)
  • Table 137. India Beta blockers, by Generation USD Million (2022-2027)
  • Table 138. South Korea Beta blockers, by Type USD Million (2022-2027)
  • Table 139. South Korea Beta blockers, by Application USD Million (2022-2027)
  • Table 140. South Korea Beta blockers, by Generation USD Million (2022-2027)
  • Table 141. Australia Beta blockers, by Type USD Million (2022-2027)
  • Table 142. Australia Beta blockers, by Application USD Million (2022-2027)
  • Table 143. Australia Beta blockers, by Generation USD Million (2022-2027)
  • Table 144. Rest of Asia-Pacific Beta blockers, by Type USD Million (2022-2027)
  • Table 145. Rest of Asia-Pacific Beta blockers, by Application USD Million (2022-2027)
  • Table 146. Rest of Asia-Pacific Beta blockers, by Generation USD Million (2022-2027)
  • Table 147. Europe Beta blockers, by Country USD Million (2022-2027)
  • Table 148. Europe Beta blockers, by Type USD Million (2022-2027)
  • Table 149. Europe Beta blockers, by Application USD Million (2022-2027)
  • Table 150. Europe Beta blockers, by Generation USD Million (2022-2027)
  • Table 151. Germany Beta blockers, by Type USD Million (2022-2027)
  • Table 152. Germany Beta blockers, by Application USD Million (2022-2027)
  • Table 153. Germany Beta blockers, by Generation USD Million (2022-2027)
  • Table 154. France Beta blockers, by Type USD Million (2022-2027)
  • Table 155. France Beta blockers, by Application USD Million (2022-2027)
  • Table 156. France Beta blockers, by Generation USD Million (2022-2027)
  • Table 157. Italy Beta blockers, by Type USD Million (2022-2027)
  • Table 158. Italy Beta blockers, by Application USD Million (2022-2027)
  • Table 159. Italy Beta blockers, by Generation USD Million (2022-2027)
  • Table 160. United Kingdom Beta blockers, by Type USD Million (2022-2027)
  • Table 161. United Kingdom Beta blockers, by Application USD Million (2022-2027)
  • Table 162. United Kingdom Beta blockers, by Generation USD Million (2022-2027)
  • Table 163. Netherlands Beta blockers, by Type USD Million (2022-2027)
  • Table 164. Netherlands Beta blockers, by Application USD Million (2022-2027)
  • Table 165. Netherlands Beta blockers, by Generation USD Million (2022-2027)
  • Table 166. Rest of Europe Beta blockers, by Type USD Million (2022-2027)
  • Table 167. Rest of Europe Beta blockers, by Application USD Million (2022-2027)
  • Table 168. Rest of Europe Beta blockers, by Generation USD Million (2022-2027)
  • Table 169. MEA Beta blockers, by Country USD Million (2022-2027)
  • Table 170. MEA Beta blockers, by Type USD Million (2022-2027)
  • Table 171. MEA Beta blockers, by Application USD Million (2022-2027)
  • Table 172. MEA Beta blockers, by Generation USD Million (2022-2027)
  • Table 173. Middle East Beta blockers, by Type USD Million (2022-2027)
  • Table 174. Middle East Beta blockers, by Application USD Million (2022-2027)
  • Table 175. Middle East Beta blockers, by Generation USD Million (2022-2027)
  • Table 176. Africa Beta blockers, by Type USD Million (2022-2027)
  • Table 177. Africa Beta blockers, by Application USD Million (2022-2027)
  • Table 178. Africa Beta blockers, by Generation USD Million (2022-2027)
  • Table 179. North America Beta blockers, by Country USD Million (2022-2027)
  • Table 180. North America Beta blockers, by Type USD Million (2022-2027)
  • Table 181. North America Beta blockers, by Application USD Million (2022-2027)
  • Table 182. North America Beta blockers, by Generation USD Million (2022-2027)
  • Table 183. United States Beta blockers, by Type USD Million (2022-2027)
  • Table 184. United States Beta blockers, by Application USD Million (2022-2027)
  • Table 185. United States Beta blockers, by Generation USD Million (2022-2027)
  • Table 186. Canada Beta blockers, by Type USD Million (2022-2027)
  • Table 187. Canada Beta blockers, by Application USD Million (2022-2027)
  • Table 188. Canada Beta blockers, by Generation USD Million (2022-2027)
  • Table 189. Mexico Beta blockers, by Type USD Million (2022-2027)
  • Table 190. Mexico Beta blockers, by Application USD Million (2022-2027)
  • Table 191. Mexico Beta blockers, by Generation USD Million (2022-2027)
  • Table 192. Beta blockers: by Type(USD/Units)
  • Table 193. Research Programs/Design for This Report
  • Table 194. Key Data Information from Secondary Sources
  • Table 195. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Beta blockers: by Type USD Million (2016-2021)
  • Figure 5. Global Beta blockers: by Application USD Million (2016-2021)
  • Figure 6. Global Beta blockers: by Generation USD Million (2016-2021)
  • Figure 7. South America Beta blockers Share (%), by Country
  • Figure 8. Asia Pacific Beta blockers Share (%), by Country
  • Figure 9. Europe Beta blockers Share (%), by Country
  • Figure 10. MEA Beta blockers Share (%), by Country
  • Figure 11. North America Beta blockers Share (%), by Country
  • Figure 12. Global Beta blockers: by Type USD/Units (2016-2021)
  • Figure 13. Global Beta blockers share by Players 2021 (%)
  • Figure 14. Global Beta blockers share by Players (Top 3) 2021(%)
  • Figure 15. Global Beta blockers share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Laboratoires Pierre Fabre (France) Revenue, Net Income and Gross profit
  • Figure 18. Laboratoires Pierre Fabre (France) Revenue: by Geography 2021
  • Figure 19. Lupin Limited (India) Revenue, Net Income and Gross profit
  • Figure 20. Lupin Limited (India) Revenue: by Geography 2021
  • Figure 21. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2021
  • Figure 23. ANIP Acquisition Company (United States) Revenue, Net Income and Gross profit
  • Figure 24. ANIP Acquisition Company (United States) Revenue: by Geography 2021
  • Figure 25. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 26. Mylan (United States) Revenue: by Geography 2021
  • Figure 27. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Novartis (Switzerland) Revenue: by Geography 2021
  • Figure 29. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 30. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2021
  • Figure 31. Teva Pharmaceutical (Israel) Revenue, Net Income and Gross profit
  • Figure 32. Teva Pharmaceutical (Israel) Revenue: by Geography 2021
  • Figure 33. King Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 34. King Pharmaceuticals (United States) Revenue: by Geography 2021
  • Figure 35. Amneal Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 36. Amneal Pharmaceuticals (United States) Revenue: by Geography 2021
  • Figure 37. Global Beta blockers: by Type USD Million (2022-2027)
  • Figure 38. Global Beta blockers: by Application USD Million (2022-2027)
  • Figure 39. Global Beta blockers: by Generation USD Million (2022-2027)
  • Figure 40. South America Beta blockers Share (%), by Country
  • Figure 41. Asia Pacific Beta blockers Share (%), by Country
  • Figure 42. Europe Beta blockers Share (%), by Country
  • Figure 43. MEA Beta blockers Share (%), by Country
  • Figure 44. North America Beta blockers Share (%), by Country
  • Figure 45. Global Beta blockers: by Type USD/Units (2022-2027)
Some of the key companies/manufacturers profiled in the report
  • Laboratoires Pierre Fabre (France)
  • Lupin Limited (India)
  • GlaxoSmithKline (United Kingdom)
  • ANIP Acquisition Company (United States)
  • Mylan (United States)
  • Novartis (Switzerland)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Teva Pharmaceutical (Israel)
  • King Pharmaceuticals (United States)
  • Amneal Pharmaceuticals (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation